Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
Kronos Bio, Inc. (Nasdaq: KRON) is a clinical-stage biopharmaceutical company committed to transforming patient outcomes through the discovery and development of novel cancer therapeutics. With a focus on modulating historically challenging cancer targets, the company leverages industry-leading high-throughput screening strategies and its proprietary small molecule microarray (SMM) platform. Kronos Bio's core business revolves around developing therapies that target the deregulated transcription processes fundamental to many cancers.
The company's most prominent projects include KB-0742, an inhibitor of CDK9, which has shown promising anti-tumor activity and a manageable safety profile in early trials involving patients with transcriptionally addicted solid tumors. The ongoing phase 1/2 trial has recently escalated dosing to 80 mg, with expansion cohort data anticipated in mid-2024.
Another key development is KB-9558, targeting the lysine acetyltransferase (KAT) domain of p300, a crucial component in the IRF4 transcription regulatory network. This molecule is currently in IND-enabling studies, expected to be completed by Q4 2024. KB-9558 aims to provide a novel treatment for multiple myeloma, a disease driven by IRF4, for which existing therapies are not curative.
Despite deciding not to advance the phase 1b/2 trial of lanraplenib in combination with gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia (AML) to phase 2, Kronos Bio remains open to further developing lanraplenib with a partner. The company emphasizes its strong biological rationale and engagement in target modulation in AML, even though it did not observe sufficient response in the study population.
Under the leadership of President and CEO Dr. Norbert Bischofberger, Kronos Bio continues to innovate, focusing on mapping transcription regulatory networks (TRNs) to identify and target key modulators, ultimately leading to the development of novel drug candidates. The company's latest structural and leadership changes are designed to streamline operations and ensure efficient delivery on business objectives.
Kronos Bio is based in San Mateo, Calif., with a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com/ or follow the company on LinkedIn.
Kronos Bio, Inc. (Nasdaq: KRON) announced the appointment of Dr. Roger Dansey to its Board of Directors on April 24, 2023. Dr. Dansey, an expert in oncology drug development, currently serves as the president of research and development at Seagen Inc. His extensive experience includes senior leadership roles at Merck, Gilead Sciences, and Amgen. CEO Norbert Bischofberger welcomed Dr. Dansey, emphasizing his deep understanding of the clinical research landscape, which will significantly aid Kronos in advancing its product portfolio targeting dysregulated transcription. The company is pursuing two investigational compounds, KB-0742 for MYC-amplified tumors and lanraplenib for FLT3-mutated acute myeloid leukemia, highlighting its focus on innovative cancer therapies.
Kronos Bio, Inc. (Nasdaq: KRON) announced the appointment of Katherine Vega Stultz to its Board of Directors, effective April 11, 2023, following the departure of Otello Stampacchia, Ph.D. on March 31, 2023. Stultz brings over 25 years of biopharmaceutical experience, currently serving as CEO of Ocelot Bio and previously holding significant roles at Graphite Bio and Celgene. CEO Norbert Bischofberger expressed confidence that Stultz's expertise in oncology drug development will enhance Kronos' clinical pipeline efforts. Kronos Bio focuses on developing therapies for challenging cancers, including investigational compounds like the CDK9 inhibitor KB-0742 and lanraplenib for acute myeloid leukemia.
Kronos Bio, Inc. (KRON) recently announced significant advancements and financial results for Q4 and FY 2022. The company has dosed its first patient in the expansion phase of its ongoing Phase 1/2 study of KB-0742, with initial efficacy data expected in late 2023. They also reported a discovery collaboration with Genentech, receiving $20 million upfront and potential total payments of $554 million. As of December 31, 2022, Kronos had $247.9 million in cash, which is expected to support operations until mid-2025. However, the company reported a net loss of $31.8 million for Q4 and $133.2 million for the full year.
Kronos Bio, Inc. (Nasdaq: KRON) announced its participation in the 43rd Annual Cowen Health Care Conference, scheduled for March 6-8, 2023, in Boston, Massachusetts. CEO Norbert Bischofberger will speak on the ‘Novel Oncology Targets’ panel on March 7 at 9:10 a.m. ET. The discussion will be available via webcast on the company’s website, with a replay accessible for 30 days post-event.
Kronos Bio focuses on developing cancer treatments, including the CDK9 inhibitor KB-0742 for MYC-amplified solid tumors and lanraplenib for FLT3-mutated acute myeloid leukemia.
FAQ
What is the current stock price of Kronos Bio (KRON)?
What is the market cap of Kronos Bio (KRON)?
What is Kronos Bio, Inc.'s core business focus?
What are the key development projects at Kronos Bio?
Where is Kronos Bio, Inc. headquartered?
What is the latest update on KB-0742?
Why did Kronos Bio decide not to proceed with lanraplenib's phase 2 trial?
What is KB-9558 and its purpose?
Who is the CEO of Kronos Bio, Inc.?
What are Kronos Bio's proprietary platforms?
How can I get more information about Kronos Bio?
What recent structural changes have occurred at Kronos Bio?
